Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis.
about
Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibioticsClinical management of infections caused by multidrug-resistant EnterobacteriaceaeDiscovery of novel new Delhi metallo-β-lactamases-1 inhibitors by multistep virtual screeningAlternating antibiotic treatments constrain evolutionary paths to multidrug resistanceGlobal assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance TrialExtraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic ResistanceGlobal Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment.Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases).The spread and acquisition of NDM-1: a multifactorial problem.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Tetracycline Antibiotics and Resistance.In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.Combination Therapy against Polymicrobial Infection, Including by NDM-1-Producing Enterobacteriaceae Resistant to Colistin.Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.Implications of direct amplification for measuring antimicrobial resistance using point-of-care devices.Use of succinic & oxalic acid in reducing the dosage of colistin against New Delhi metallo-β-lactamase-1 bacteria.
P2860
Q26783267-6BFCFC7B-F117-45F5-94E4-30F15C9A67BBQ28246841-6ACCD640-D20C-4CA3-920B-D38EF52C71D3Q28543793-2C62C9D2-C818-4905-AE1D-068372AED965Q34407557-A03C526B-BA5E-43B9-A70D-78CCC6E938E2Q35193312-2EA59942-F5D7-42D7-8049-249C6E9BDE77Q35681590-D0CC41A2-A7B6-4B35-9559-D45039F34EEEQ37593067-4B0468FE-62AF-4664-AB1D-138A0FEB0B3FQ37643705-E0F57609-91A4-469F-BD7A-E40F17F07B29Q38063968-26CD3469-3DC5-4F12-B8F2-6574D9DAC7C2Q38074212-EECE2211-D282-4779-9778-7F063AEBF0B8Q38168928-35C0CC28-E854-4D14-8E82-A8A975C9F8C6Q38286351-A2F5F271-E117-4EB8-9BA2-840390525704Q38779243-9F4499BC-7085-4CFB-B104-4F7D74FCE55BQ41904163-FD6207C9-2B77-4A55-A411-E16F9246867CQ42349300-B1B8CF9A-E3B0-4F65-B73F-51AB609FEA99Q46152898-068D1426-B539-4111-825F-853E692B9222Q53749612-FE05A215-FC72-43A6-983F-C5532B4F6759Q55286457-E5705A21-8A16-4E97-B7A6-7F043839DF40
P2860
Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Breakthrough bacteraemia due t ...... a patient with calciphylaxis.
@en
Breakthrough bacteraemia due t ...... New Delhi metallo-β-lactamase
@nl
type
label
Breakthrough bacteraemia due t ...... a patient with calciphylaxis.
@en
Breakthrough bacteraemia due t ...... New Delhi metallo-β-lactamase
@nl
prefLabel
Breakthrough bacteraemia due t ...... a patient with calciphylaxis.
@en
Breakthrough bacteraemia due t ...... New Delhi metallo-β-lactamase
@nl
P2093
P356
P1476
Breakthrough bacteraemia due t ...... a patient with calciphylaxis.
@en
P2093
Claire Perry
David M Livermore
Julia Howard
Neil R H Stone
Rachel Pike
Shazad Mushtaq
P304
P356
10.1093/JAC/DKR337
P407
P577
2011-08-16T00:00:00Z